[Evidence-based recommendations for the treatment of fibromyalgia syndrome].
Schwerpunktpraxis Internistische Rheumatologie, Sophienblatt 1, Kiel, Germany. p.harten@web.de
P
P
Harten
E
E
Genth
D018759:Adrenergic Uptake Inhibitors / Q000627:therapeutic use; D000700:Analgesics / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003245:Consensus Statements as Topic; D003430:Cross-Sectional Studies; D000068736:Duloxetine Hydrochloride; D019317:Evidence-Based Medicine; D005081:Exercise Therapy; D005356:Fibromyalgia / Q000453:epidemiology / Q000534:rehabilitation*; D006801:Humans; D017410:Practice Guidelines as Topic; D000069583:Pregabalin; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D013876:Thiophenes / Q000627:therapeutic use; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives / Q000627:therapeutic use
D018759:Adrenergic Uptake Inhibitors; D000700:Analgesics; D000928:Antidepressive Agents; D000068736:Duloxetine Hydrochloride; D000069583:Pregabalin; D017367:Selective Serotonin Reuptake Inhibitors; D013876:Thiophenes; D005680:gamma-Aminobutyric Acid
Evidenzbasierte Empfehlungen zur Therapie des Fibromyalgiesyndroms.